{"id":"insulin-glargine-u300","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201497","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin glargine is a recombinant human insulin analog with an extended duration of action due to its formulation and pharmacokinetic properties. The U300 formulation (300 units/mL) provides a higher concentration, allowing for smaller injection volumes while maintaining steady basal insulin levels for approximately 24 hours or longer. It works by mimicking endogenous insulin to regulate glucose metabolism and maintain euglycemia in diabetic patients.","oneSentence":"Insulin glargine (U300) is a long-acting basal insulin that binds to insulin receptors on muscle and fat cells to promote glucose uptake and reduce blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:10.652Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07173712","phase":"PHASE4","title":"Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Yanbing Li","startDate":"2026-03-15","conditions":"Type 2 Diabetes","enrollment":324},{"nctId":"NCT05002933","phase":"PHASE4","title":"A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-05-20","conditions":"Type 2 Diabetes Mellitus","enrollment":570},{"nctId":"NCT04980027","phase":"PHASE4","title":"Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-06-07","conditions":"Type 2 Diabetes Mellitus","enrollment":228},{"nctId":"NCT05552859","phase":"PHASE4","title":"Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment","status":"TERMINATED","sponsor":"Sanofi","startDate":"2022-12-05","conditions":"Type 2 Diabetes Mellitus, Renal Impairment","enrollment":62},{"nctId":"NCT05036876","phase":"NA","title":"Degludec Glargine U300 Hospital Study","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2021-10-10","conditions":"Type 2 Diabetes","enrollment":220},{"nctId":"NCT03455985","phase":"NA","title":"Effectiveness of a Diabetes Focused Discharge Order Set Among Poorly Controlled Hospitalized Patients Transitioning to Glargine U300 Insulin","status":"TERMINATED","sponsor":"Ohio State University","startDate":"2018-05-01","conditions":"Diabetes Mellitus, Type 2, Patient Discharge, Blood Glucose, Low","enrollment":158},{"nctId":"NCT04075513","phase":"PHASE4","title":"Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-10-09","conditions":"Type 1 Diabetes Mellitus","enrollment":343},{"nctId":"NCT03703869","phase":"","title":"Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-03-06","conditions":"Diabetes","enrollment":4589},{"nctId":"NCT02967224","phase":"PHASE4","title":"A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to \"Standard of Care\" Basal Insulins in Insulin Naïve Patients Initiating Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-05","conditions":"Diabetes Mellitus, Type 2","enrollment":705},{"nctId":"NCT02967237","phase":"PHASE4","title":"Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-04","conditions":"Diabetes Mellitus, Type 2","enrollment":136},{"nctId":"NCT02967211","phase":"PHASE4","title":"A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to \"Standard of Care\" Basal Insulin in Patients Already Using Basal Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-12-21","conditions":"Diabetes Mellitus, Type 2","enrollment":609},{"nctId":"NCT03760991","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-12-18","conditions":"Type 2 Diabetes Mellitus","enrollment":372},{"nctId":"NCT02855684","phase":"PHASE3","title":"Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-08-24","conditions":"Type 2 Diabetes Mellitus","enrollment":604},{"nctId":"NCT03406000","phase":"PHASE4","title":"Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-01-22","conditions":"Type I Diabetes Mellitus","enrollment":170},{"nctId":"NCT02688933","phase":"PHASE4","title":"A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-05","conditions":"Type 1 Diabetes Mellitus","enrollment":638},{"nctId":"NCT02735044","phase":"PHASE3","title":"Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-04-14","conditions":"Type 1 Diabetes Mellitus","enrollment":463},{"nctId":"NCT01499082","phase":"PHASE3","title":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-12","conditions":"Type 2 Diabetes Mellitus","enrollment":807},{"nctId":"NCT01499095","phase":"PHASE3","title":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-12","conditions":"Type 2 Diabetes Mellitus","enrollment":811},{"nctId":"NCT03328845","phase":"PHASE4","title":"Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study)","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2017-01-20","conditions":"Type 1 Diabetes Mellitus","enrollment":300},{"nctId":"NCT03389490","phase":"PHASE4","title":"Toujeo Versus NPH Self-titration Study","status":"COMPLETED","sponsor":"Elaine Chow","startDate":"2018-01-01","conditions":"Diabetes Mellitus, Type 2","enrollment":50},{"nctId":"NCT04692415","phase":"PHASE4","title":"Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors","status":"COMPLETED","sponsor":"University of Split, School of Medicine","startDate":"2018-12-15","conditions":"Diabetes Mellitus, Type 2","enrollment":25},{"nctId":"NCT03013985","phase":"PHASE4","title":"Glargine U300 Hospital Trial","status":"COMPLETED","sponsor":"Emory University","startDate":"2017-05-17","conditions":"Type 2 Diabetes","enrollment":247},{"nctId":"NCT02320721","phase":"PHASE3","title":"Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":1014},{"nctId":"NCT02536859","phase":"PHASE1","title":"Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-08-31","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":60},{"nctId":"NCT02954692","phase":"PHASE4","title":"A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-30","conditions":"Type 2 Diabetes Mellitus","enrollment":112},{"nctId":"NCT02738151","phase":"PHASE4","title":"Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-19","conditions":"Diabetes Mellitus, Type 2","enrollment":929},{"nctId":"NCT02585674","phase":"PHASE3","title":"Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-12","conditions":"Type 2 Diabetes Mellitus","enrollment":151},{"nctId":"NCT02401243","phase":"PHASE3","title":"Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-03","conditions":"Type 2 Diabetes Mellitus","enrollment":253},{"nctId":"NCT01683266","phase":"PHASE3","title":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-09","conditions":"Type 1 Diabetes Mellitus","enrollment":549},{"nctId":"NCT01676220","phase":"PHASE3","title":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-08","conditions":"Type 2 Diabetes Mellitus","enrollment":878},{"nctId":"NCT01658579","phase":"PHASE2","title":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-08","conditions":"Type 1 Diabetes Mellitus","enrollment":59},{"nctId":"NCT02227212","phase":"PHASE3","title":"Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-08","conditions":"Diabetes Mellitus Type 2","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HOE901 Toujeo","Toujeo, HOE901","HOE901","HOE901, Toujeo, Gla-300","HOE901, Toujeo, Toujeo Solostar"],"phase":"marketed","status":"active","brandName":"Insulin glargine (U300)","genericName":"Insulin glargine (U300)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin glargine (U300) is a long-acting basal insulin that binds to insulin receptors on muscle and fat cells to promote glucose uptake and reduce blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}